evidence table
Berberine Blood Pressure Meta-Analysis Evidence Table
Structured evidence table for Berberine Blood Pressure Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Berberine Blood Pressure Meta-Analysis | This review was based on a narrative literature search designed to identify experimental, clinical, and translational evidence linking natural products with gut barrier integrity, gut microbiota, low-grade inflammation, and metabolic endotoxemia. | 3 | Šantić Roko (2026) | Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives |
| Berberine Blood Pressure Meta-Analysis | Because this article is a narrative review rather than a systematic review, formal risk-of-bias assessment and quantitative evidence synthesis were not performed. | 3 | Šantić Roko (2026) | Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives |
| Berberine Blood Pressure Meta-Analysis | Over the past two decades, accumulating evidence has repositioned the gastrointestinal tract from a passive absorptive organ to an immunologically active barrier whose functional state directly influences systemic inflammatory tone and metabolic homeostasis []. | 3 | Šantić Roko (2026) | Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives |
| Berberine Blood Pressure Meta-Analysis | Reference lists of relevant reviews and primary studies were additionally screened to identify articles not captured by database searches. | 3 | Šantić Roko (2026) | Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives |
| Berberine Blood Pressure Meta-Analysis | The primary prevention of CVD through the management of dyslipidemia, a major risk factor for CVD, is a critical strategy for improving population health outcomes and reducing the associated economic impact. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
| Berberine Blood Pressure Meta-Analysis | Statin use has increased substantially in recent years, with nearly two-thirds of those taking statins for primary prevention. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
| Berberine Blood Pressure Meta-Analysis | The clinical guidelines also recommend statin use among people previously considered at low risk of CVD. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
| Berberine Blood Pressure Meta-Analysis | 1 2 4 – 5 6 , 7 4 8 10 ,– 11 12 13 16 – Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, which poses a heavy burden on healthcare. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
Source documents